{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T13:45:22Z","timestamp":1764510322280},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2004,4,1]]},"DOI":"10.1532\/ijh97.03071","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T13:52:32Z","timestamp":1192715552000},"page":"266-270","source":"Crossref","is-referenced-by-count":9,"title":["Phase I Study of the Combination of Irinotecan Hydrochloride, Carboplatin, and Dexamethasone for the Treatment of Relapsed or Refractory Malignant Lymphoma"],"prefix":"10.1007","volume":"79","author":[{"given":"Junji","family":"Suzumiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Suzushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouichi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atae","family":"Utsunomiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tunefumi","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyushu Hematology Organization for","family":"Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1182\/blood.V71.1.117.117","author":"Velasquez, WS","year":"1988","unstructured":"Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988;71:117-122.","journal-title":"Blood"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","volume":"12","author":"Velasquez, WS","year":"1994","unstructured":"Velasquez WS, McLaughlin P,Tucker S, et al. ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169-1176.","journal-title":"J Clin Oncol"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1200\/JCO.2000.18.21.3633","volume":"18","author":"Gutierrez, M","year":"2000","unstructured":"Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633-3642.","journal-title":"J Clin Oncol"},{"key":"E00004","first-page":"635","author":"Okamoto, M","year":"1994","unstructured":"Okamoto M, Maruyama F, Tsuzuki M, et al. Salvage chemotherapy for relapsed\/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carbo-platin [in Japanese]. Rinsho Ketsueki. 1994;35:635-641.","journal-title":"Rinsho Ketsueki"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/BF00262744","volume":"21","author":"Tsuruo, T","year":"1988","unstructured":"Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol. 1988;21:71-74.","journal-title":"Cancer Chemother Pharmacol"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1200\/JCO.1990.8.11.1907","volume":"8","author":"Ohno, R","year":"1990","unstructured":"Ohno R, Okada K, Masaoka T, et al. An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma. J Clin Oncol. 1990;8:1907-1912.","journal-title":"J Clin Oncol"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/oxfordjournals.jjco.a039642","author":"Tobinai, K","year":"1993","unstructured":"Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group: the Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993;23:250-257.","journal-title":"Jpn J Clin Oncol"},{"key":"E00008","unstructured":"World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979:48."},{"key":"E00009","first-page":"4187","volume":"51","author":"Kawato, Y","year":"1991","unstructured":"Kawato Y,Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51:4187-4191.","journal-title":"Cancer Res"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"577","DOI":"10.3109\/10428190109099317","volume":"4","author":"Takagi, T","year":"2001","unstructured":"Takagi T, Saotome T. Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;4:577-586.","journal-title":"Leuk Lymphoma"},{"key":"E00011","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/bjc.1994.394","volume":"70","author":"Tsuda, H","year":"1994","unstructured":"Tsuda H, Takatsuki K, Ohno R, et al. Treatment of adult T-cell leukaemia-lymphoma with irinotecan hydrochloride (CPT-11): CPT-11 Study Group on Hematological Malignancy. Br J Cancer. 1994;70:771-774.","journal-title":"Br J Cancer"},{"key":"E00012","first-page":"21","volume":"23","author":"Rothenberg, ML","year":"1996","unstructured":"Rothenberg ML. CPT-11: an original spectrum of clinical activity. Semin Oncol. 1996;23(suppl 3):21-26.","journal-title":"Semin Oncol"},{"key":"E00013","first-page":"1047","volume":"21","author":"Ota","year":"1994","unstructured":"Ota K, Ohno R, Shirakawa S, et al. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia: the CPT-11 Research Group for Hematological Malignancies [in Japanese]. Gan To Kagaku Ryoho. 1994;21:1047-1055.","journal-title":"Gan To Kagaku Ryoho"},{"key":"E00014","first-page":"1607","volume":"21","author":"Akutsu, M","year":"1994","unstructured":"Akutsu M, Suzuki K, Tsunoda S, Kano Y, Miura Y. Effects of SN-38 in combination with other anticancer agents against Dauji cells [in Japanese]. Gan To Kagaku Ryoho. 1994;21:1607-1611.","journal-title":"Gan To Kagaku Ryoho"},{"key":"E00015","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumors: Tumors of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"E00016","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/oxfordjournals.jjco.a023263","volume":"26","author":"Tobinai, K","year":"1996","unstructured":"Tobinai K, Hotta T, Saito H, et al. Combination phase I\/II study of irinotecan hydrochloride (CPT-11) and carboplatin in relapsed or refractory non-Hodgkin's lymphoma: CPT- 11\/Lymphoma Study Group. Jpn J Clin Oncol. 1996;26:455-460.","journal-title":"Jpn J Clin Oncol"},{"key":"E00017","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.1992.10.1.16","volume":"10","author":"Fukuoka, M","year":"1992","unstructured":"Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol. 1992;10:16-20.","journal-title":"J Clin Oncol"},{"key":"E00018","first-page":"1681","volume":"18","author":"Takeuchi, S","year":"1991","unstructured":"Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer: Research Groups of CPT-11 in Gynecologic Cancers [in Japanese]. Gan To Kagaku Ryoho. 1991;18:1681-1689.","journal-title":"Gan To Kagaku Ryoho"},{"key":"E00019","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.1993.11.5.909","volume":"11","author":"Shimada, Y","year":"1993","unstructured":"Shimada Y, Yoshino M, Wakui A, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer: CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol. 1993; 11:909-913.","journal-title":"J Clin Oncol"},{"key":"E00020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/cncr.10266","author":"Sugiyama, K","year":"2002","unstructured":"Sugiyama K, Omachi K, Fujiwara K, et al. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience. Cancer. 2002;94:594-600.","journal-title":"Cancer"},{"key":"E00021","first-page":"2145","author":"Naito, K","year":"1988","unstructured":"Naito K, Kobayashi M, Oyama A, et al. Phase II study of carboplatin in malignant lymphoma [in Japanese]. Gan To Kagaku Ryoho. 1988;15:2145-2151.","journal-title":"Gan To Kagaku Ryoho"},{"key":"E00022","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ijc.2910500420","volume":"50","author":"Kano, Y","year":"1992","unstructured":"Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer. 1992;50: 604-610.","journal-title":"Int J Cancer"},{"key":"E00023","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1008368905546","author":"Saotome, T","year":"2000","unstructured":"Saotome T, Takagi T, Sakai C, Kumagai K, Tamaru J. Combination chemotherapy with irinotecan and Adriamycin for refractory and relapsed non-Hodgkin's lymphoma. Ann Oncol. 2000;11:115-116.","journal-title":"Ann Oncol"},{"key":"E00024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s002770100313","volume":"80","author":"Niitsu, N","year":"2001","unstructured":"Niitsu N, Iijima K, Chizuka A. Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study. Ann Hematol. 2001;80:411-416.","journal-title":"Ann Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.03071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T07:47:07Z","timestamp":1587973627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.03071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,4,1]]}},"alternative-id":["1BEU228T5D0HRVHX"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.03071","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}